Paper - WANFANG MED ONLINE

You Position: Home > Paper

Antitumor mechanism and clinical application of anti-PD-1 agents in cutaneous tumors

( views:16, downloads:16 )

Author:: No author available

Journal Title:: International Journal of Dermatology and Venereology

Issue:: 1

DOI:: 10.3760/cma.j.issn.2096-5540.2018.01.006

Key Word:: No keyword available

Abstract： IntroductionProgrammed death-1 (PD-1) is an inhibitory T-cell receptor expressed by activated T-lymphocytes,and its two major ligands are PD-L1 (B7-H1,CD274) and PD-L2 (B7-DC,CD273).Under normal conditions,PD-L1 is mainly expressed on T cells,B cells,dendritic cells,and macrophages,whereas PD-L2 is expressed selectively on activated dendritic cells,macrophages,marrow-originated mast cells,and peritoneum B1 cells.

Reference

[1]Kantekure,K.,Wasik,M.,Woetmann,A.,etc.Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides[J].2012,34(1).
[2]Shoba, Amarnath,Courtney W, Mangus,James C M, Wang,etc.The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.[J].2011,3(111).
[3]Lijuan Han,Feifei Liu,Ruping Li,etc.Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.[J].2014,8(4).
[4]Park,J.-H.,Han,J.H.,Kang,H.Y.,etc.Expression of follicular helper T-cell markers in primary cutaneous t-cell Lymphoma[J].2014,36(6).
[5]Takeo, Nomi,Masayuki, Sho,Takahiro, Akahori,etc.Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.[J].2007,13.
[6]Ribas, Antoni,Hamid, Omid,Daud, Adil,etc.Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma[J].2016,315(15).
[7]Norris,S.,Bower,M.,Kuri-Cervantes,L.,etc.PD-1 expression on natural killer cells and CD8 + T cells during chronic HIV-1 infection[J].2012,25(4).
[8]Nghiem, Paul T.,Bhatia, Shailender,Lipson, Evan J.,etc.PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma[J].2016,374(26).
[9]Shuo, Wang,Yonghua, Wang,Jing, Liu,etc.Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro.[J].2014,7.
[10]Lesokhin, Alexander M.,Ansell, Stephen M.,Armand, Philippe,etc.Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study[J].2016,34(23).
[11]Wherry EJ,Wysocka M,Showe L,etc.Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.[J].2010,146(12).
[12]Gerald S, Falchook,Rom, Leidner,Elizabeth, Stankevich,etc.Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.[J].2016,(Spec ).
[13]Kurts, C.,Ludwig-Portugall, I.,Leopold, S.,etc.Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo[J].2012,109(26).
[14]Udager, A. M.,Liu, T. -Y.,Skala, S. L.,etc.Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches[J].2016,27(9).
[15]Ahmadzadeh M,Johnson LA,Heemskerk B.Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.[J].2009,114(8).
[16]Stevenson, Mary L.,Wang, Claire Q. F.,Abikhair, Melody,etc.Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab[J].2017,153(4).
[17]Larkin, J.,Chiarion-Sileni, V.,Gonzalez, R.,etc.Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[J].2015,373(1).
[18]Lipson Evan J.,Lilo Mohammed T.,Ogurtsova Aleksandra,etc.Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade[J].2017,5(1).
[19]Linette, Gerald P.,Lorch, Jochen H.,Kaufman, Howard L.,etc.Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial[J].2016,17(10).
[20]Stefani, Spranger,Holly K, Koblish,Brendan, Horton,etc.Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.[J].2014,2.
[21]Wang C,Lau RL,Weber JS,etc.Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.[J].2007,19(10).
[22]Weber J.Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.[J].2010,37(5).
[23]Klemke, C. D.,Booken, N.,Weiss, C.,etc.Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 9[J].2015,173(1).
[24]Afanasiev,O.K.,Yelistratova,L.,Miller,N.,etc.Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and tim-3 exhaustion markers[J].2013,19(19).
[25]Yagita H,Shao Z,Agrawal DK,etc.Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma.[J].2010,43(4).